The cascade of metastasis in tumor cells, exhibiting organ-specific tendencies, may occur at
numerous phases of the disease and progress under intense evolutionary pressures. Organ …

In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …

The BEACON CRC study demonstrated that encorafenib (Enco)+ cetuximab
(Cetux)±binimetinib (Bini) significantly improved overall survival (OS) versus Cetux+ …

Background Combination of a BRAF inhibitor (BRAFi) and an anti-epidermal growth factor
receptor (EGFR), with or without a MEK inhibitor (MEKi), improves survival in BRAF-V600E …

DNA variation analysis has become indispensable in many aspects of modern biomedicine,
most prominently in the comparison of normal and tumor samples. Thousands of samples …

Introduction The presence of a BRAF-V600E mutation in metastatic colorectal cancer
(mCRC) is observed in approximately 12% of cases and is associated with poor prognosis …

Aims This study aimed to identify mechanisms of drug resistance to the combination of
vemurafenib, irinotecan, and cetuximab (VIC) in BRAF V600E metastatic colorectal cancer …

Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic
alterations. The BRAF V600E mutation occurs in approximately 8–12% of patients and is …

Colorectal cancer (CRC) remains a leading cause of cancer-related deaths worldwide. In
recent years, liquid biopsy has emerged as one of the most interesting areas of research in …

Lung cancer is a lethal malignancy lacking effective therapies. Emerging evidence suggests
that epigenetic enzyme mutations are closely related to the malignant phenotype of lung …